Clinical Trials Browser

Leukemia × midostaurin × 90 days × Clear all

NCT06313437 2026-03-25

Revumenib in Combination With 7+3 + Midostaurin in AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute